Immunovant, Inc. (NASDAQ:IMVT – Get Rating) has been given an average recommendation of “Moderate Buy” by the thirteen research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target […]

Related Keywords

Peter Salzmann , Eva Renee Barnett , Piper Sandler , Barclays Plc , Principal Financial Group Inc , Ensign Peak Advisors Inc , Immunovant Inc , Cantor Fitzgerald , Nasdaq , Nisa Investment Advisors , Citigroup , Securities Exchange Commission , Get Rating , Exchange Commission , Renee Barnett , Peak Advisors Inc , Investment Advisors , Principal Financial Group , Financial Group , Trading Down , Immunovant Daily , Immunovant , Nasdaq Imvt , Imvt , Medical , Ratings , Consensus ,